GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Last trade$46.64
Day change-$4.38 (-8.58%)
Day range$44.34 – $51.99
Volume1,414,627
Market cap$1.53B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.53B
Price / earnings
—
Price / book
6.25×
Price / sales
3.32×
EV / sales
3.43×
EV / EBITDA
-38.52×
Profitability
Earnings per share
-$3.71
Return on assets
-21.14%
Return on equity
-45.49%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.6×
Current ratio
4.16×
Quick ratio
3.85×
Cash ratio
1.35×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$101.22M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for WGS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$123.1M
$114.44M
$102.25M
$120.99M
$116.74M
$102.69M
$87.12M
$95.64M
Cost of revenue
$37.04M
$36.2M
$34.04M
$36.72M
$32.22M
$31.79M
$28.64M
$29.44M
Gross profit
$86.06M
$78.24M
$68.21M
$84.27M
$84.53M
$70.9M
$58.48M
$66.21M
Selling, general and administrative
$79.12M
$76.04M
$74.59M
$73.96M
$67.95M
$46.86M
$50.45M
$45.81M
Research and development
$17.37M
$19.66M
$19.8M
$24.54M
$19.83M
$15.08M
$12.58M
$11.59M
Total operating expenses
$96.49M
$95.69M
$125.68M
$98.5M
$87.78M
$61.94M
$63.03M
$57.4M
Operating income
-$10.43M
-$17.46M
-$57.47M
-$14.24M
-$3.25M
$8.96M
-$4.55M
$8.81M
Interest expense
-$1.78M
-$1.19M
-$717K
$0
-$562K
-$817K
-$640K
$0
Income before taxes
-$12.3M
-$18.26M
-$62.42M
-$18.23M
-$7.39M
$10.56M
-$6.08M
$5.41M
Income taxes
$26K
-$518K
$897K
-$564K
$247K
-$246K
$447K
-$24K
Net income
-$12.33M
-$17.74M
-$63.32M
-$17.67M
-$7.64M
$10.81M
-$6.53M
$5.44M
Net income attributable to common shareholders
-$12.33M
-$17.74M
-$63.57M
-$17.67M
-$7.64M
$10.81M
-$6.45M
$5.44M
EBITDA
-$3.53M
-$10.74M
-$19.38M
-$7.35M
$3.22M
$15.15M
$1.13M
$14.36M
Basic earnings per share
-$0.41
-$0.60
-$2.16
-$0.61
-$0.27
$0.38
-$0.23
$0.20
Diluted earnings per share
-$0.41
-$0.60
-$2.16
-$0.63
-$0.27
$0.36
-$0.23
$0.20
Recent news
Company coverage with links to the original publishers.
GeneDx Holdings stock fell 16.6% after the company reported Q3 results that met revenue expectations at $123.1 million but fell short on testing volume growth. The company lowered its 2026 volume growth target to at least 28% from the previously promised 29.2% or more, marking the second downward revision this year. While the genetic testing company continues to grow, investors are concerned about the deceleration in core business metrics.
GeneDx Holdings (WGS) reported quarterly earnings of $0.28 per share, significantly beating consensus estimates of $0.07, representing a 300% surprise. However, the stock has underperformed the market by 52.1% year-to-date. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Agilon Health (AGL) reported quarterly earnings of $1.97 per share, significantly beating consensus estimates of a loss of $2.01 per share, representing a +198% earnings surprise. The company posted revenues of $1.52 billion, surpassing estimates by 4.43%. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Agilon shares have gained 409.9% year-to-date, substantially outperforming the S&P 500's 10.6% gain.
Encompass Health Corporation (EHC) opened its first wholly owned hospital in Maine with 50 inpatient rehabilitation beds. Q2 2026 discharges rose 5.6% year-over-year, driven by new capacity and 2.8% same-store growth. EHC opened three hospitals in the first half of 2026 and plans to open eight new hospitals throughout the year, reflecting its strategy to expand capacity in favorable markets.
The State Street SPDR S&P Health Care Services ETF (XHS) is a passively managed healthcare services sector ETF with low costs (0.35% expense ratio) and solid year-to-date performance of 27.29%. The fund holds about 62 healthcare companies with a medium risk profile (beta of 0.93) and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable option for investors seeking diversified healthcare sector exposure.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.